Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19GlobeNewsWire • 06/29/20
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis BGlobeNewsWire • 06/22/20
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19GlobeNewsWire • 06/01/20
Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?Zacks Investment Research • 05/15/20
Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/14/20
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/13/20
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of DirectorsGlobeNewsWire • 05/12/20
COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of AlabamaBenzinga • 03/30/20
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 VaccineGlobeNewsWire • 03/30/20
Altimmune's Coronavirus Spike, And Other News: The Good, Bad, And Ugly Of BiopharmaSeeking Alpha • 03/04/20
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal CancerGlobeNewsWire • 01/23/20
Altimmune's (ALT) CEO Vipin Garg on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/15/19